T1	Participants 28 74	completely resected non-small-cell lung cancer
T2	Participants 133 201	patients with completely resected non-small-cell lung cancer (NSCLC)
T3	Participants 416 561	Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy
T4	Participants 758 810	503 of 1,242 planned patients were randomly assigned
T5	Participants 1278 1352	344 patients with epidermal growth factor receptor (EGFR) wild-type tumors
T6	Participants 1505 1551	15 patients with EGFR mutation-positive tumors
